MonoSol Rx, a specialty pharmaceutical company, closed a $50 million credit facility with Perceptive Advisors. The proceeds from the credit facility will be used to repay an existing debt facility with White Oak Global Advisors and to advance the company’s clinical-stage drug candidates, including prospects in its CNS portfolio.

“Securing a sizeable credit facility with a leading global life sciences fund such as Perceptive Advisors is a significant accomplishment for MonoSol Rx and provides an important validation for the company and our PharmFilm technology platform,” said Keith Kendall, CEO of MonoSol Rx.

“MonoSol Rx represents a unique opportunity in the specialty pharmaceutical space. With their proprietary PharmFilm technology, they have built a robust portfolio of commercial products and promising clinical candidates,” added Sam Chawla, portfolio manager at Perceptive Advisors.

Perceptive Advisors is focused on supporting the progress of the life sciences industry by identifying opportunities and directing financial resources to the most promising technologies in healthcare.